《新股消息》传新石文化(01740.HK)公开发售超购逾1,000倍
市场消息指,今日(8日)截止招股的新石文化(01740.HK)公开发售超购逾1,000倍。
新石文化从事授出电视剧播放权许可、以非执行制作人身份投资电视剧,及担任电视剧发行代理。是次在港上市计划发售股份数目2.5亿股,其中10%於本港公开发售,招股价介乎0.5元至0.74元,每手5,000股,入场费3,737.28元。股份预期於明日(9日)定价,1月16日挂牌上市。
以招股价中位数每股0.62元计,料是次上市集资净额1.15亿元,其中86.9%将用於制作电视剧,另外13.1%将用於购买与电视剧有关的版权或播放权。是次上市之独家保荐人及独家全球协调人为中泰国际。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.